Cellectar Shares Surge on Promising Clinical Developments
Published on 11/26/2025 at 08:12 | Redaktion boerse-global.de
The biotechnology sector is witnessing notable momentum in Cellectar Biosciences, with the company’s stock demonstrating substantial upward movement following significant clinical progress. Investor attention has intensified around Cellectar’s targeted radiopharmaceutical pipeline, particularly its lead candidates iopofosine I-131 and CLR 121225.
Recent regulatory recognition has provided substantial momentum for Cellectar. The U.S. Food and Drug Administration granted Rare Pediatric Disease designation to iopofosine I-131 for treating pediatric high-grade glioma that is inoperable, relapsed, or refractory. This designation highlights the therapy’s potential in addressing this challenging childhood cancer.
Supporting data from the Phase 1b CLOVER-2 trial revealed encouraging interim results:
* Patients receiving minimum total doses of 55 mCi Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
